Study identifier:D144CC00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel SR®) Sustained-release as Monotherapy in Adult Patients with Acute Bipolar Depression
Affective Psychosis, Bipolar
Phase 3
No
Quetiapine fumarate (Seroquel) SR
All
400
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Depression for 8 weeks. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Location
Location
BIRMINGHAM, AL, United States
Location
LITTLE ROCK, AR, United States
Location
PHOENIX, AZ, United States
Location
SCOTTSDALE, AZ, United States
Location
CERRITOS, CA, United States
Location
LA MESA, CA, United States
Location
LOS ANGELES, CA, United States
Location
NEWPORT BEACH, CA, United States
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.